This is a type of cancer treatment that uses specially weakened viruses. These viruses are designed to find and attack cancer cells, killing them off. It's a way to fight cancer using viruses that are safe enough to be used in people.
Every report comes from a Lived member, sent anonymously.
Have you tried Oncolytic Virotherapy for Melanoma?
Oncolytic virotherapy treats cancer with viruses that have been modified to infect and multiply inside tumor cells while largely sparing normal tissue. As the virus copies itself, the infected cancer cells break apart and die, releasing more virus that can reach neighboring tumor cells. The second effect may matter as much as the first. Dying tumor cells spill out proteins that help the immune system recognize the cancer, and some viruses are engineered to carry a gene that further stimulates immune cells. In that sense, virotherapy is a form of immunotherapy, and a response can sometimes extend beyond the tumors that were injected. Exactly how much each effect contributes is still not fully understood.
In the US, one oncolytic virus is approved: talimogene laherparepvec (T-VEC, sold as Imlygic), a weakened, genetically modified version of herpes simplex virus type 1, the cold sore virus. It is used for melanoma that has come back after surgery and has tumors in or under the skin or in lymph nodes that cannot be removed surgically. It is a local treatment, so it suits people whose disease includes lesions a clinician can reach with a needle. It is not used for melanoma that has spread only to internal organs such as the lung or liver, and it is not given during pregnancy or to people with a weakened immune system. A different herpes-based virus has been approved in Japan for recurrent brain tumors. Other oncolytic viruses, being tested in many kinds of cancer, are available only through clinical trials.
A clinician injects the virus directly into selected tumors with a needle, using ultrasound to guide injections into deeper nodes. The first visit uses a lower strength of the virus. A second treatment at full strength follows three weeks later, then injections every two weeks. Treatment usually continues for at least six months, or until there are no tumors left to inject. Not every tumor is injected at each visit, and new tumors are typically treated first. Because the treatment is a live virus, the injection sites need care at home. They are kept covered with airtight, watertight dressings for at least a week after each visit (longer if they ooze), dressings are changed with gloves and thrown away sealed in a plastic bag, and the sites should not be touched or scratched. Household members, caregivers and sex partners should avoid contact with the sites, dressings and body fluids, and anyone who is pregnant or has a weakened immune system should not handle them at all.
Flu-like symptoms are the most common experience: tiredness, chills, fever, nausea and soreness where the injection went in. These are usually mild to moderate, tend to settle within about three days, and are more frequent in the first three months of treatment. Results take time. In the main melanoma trial, people who responded typically did so around four months after starting, and treatment was continued for at least six months even if tumors grew or new ones appeared early on. For that reason, care teams do not usually judge the treatment on a single early scan. Injected tumors can also break down into open sores as cancer tissue dies, which calls for careful wound care. Progress is followed with regular visits, measurements of the treated tumors and periodic imaging.
The approval of T-VEC rests on a large randomized trial in people with advanced melanoma that could not be removed surgically. About 16 in 100 people treated with T-VEC had tumors shrink and stay smaller for at least six months, compared with about 2 in 100 who received a comparison immune-stimulating drug. In some people the tumors disappeared completely, and these complete responses were linked with longer survival. However, the treatment has not been shown to help people live longer overall, and it has not been shown to shrink cancer in internal organs. Combining it with modern immunotherapy has given mixed results. Adding T-VEC to ipilimumab, a checkpoint inhibitor immunotherapy, increased the share of people whose tumors shrank, but a large trial adding it to pembrolizumab, another checkpoint inhibitor, found no improvement in how long people lived or stayed free of progression. For other cancers, most evidence comes from early or small trials without comparison groups, so benefit is not established.
The most important risk comes from the virus itself. T-VEC can cause herpes infections, from cold sores to infection of the eye, and rarely infection that spreads through the body, which has been fatal in people with weakened immune systems. That is why it is not given to people with immune deficiencies, advanced HIV infection, leukemia or lymphoma, or those taking steroids or other immune-suppressing medicines, and why it is not given during pregnancy. People who could become pregnant are advised to use effective birth control during treatment. Contact the care team right away for blisters, burning or tingling around the mouth, genitals or anywhere on the body, for eye pain, light sensitivity, discharge or blurry vision, or for new weakness in the arms or legs, unusual drowsiness or confusion. Close contacts with similar symptoms should also be checked. Herpes antiviral medicines such as acyclovir can blunt the treatment, so tell the team before taking one. Injected tumors can become infected or heal slowly, especially in skin that was previously treated with radiation. Immune-related inflammation, such as worsening psoriasis, has been reported, which matters for people with autoimmune disease. Frequent visits over many months are a real time commitment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Oncolytic Virotherapy, what's helped you, or ask the community a question.